GLP-1s and Cholesterol in Menopause: What Actually Happens to Your Lipids

Cholesterol rises during menopause because estrogen directly regulates how the liver clears LDL particles from the bloodstream, and when estrogen falls, that clearance slows.

The mechanism is specific. Estrogen upregulates LDL receptors on liver cells - these are the proteins that pull LDL particles out of circulation. Fewer receptors means LDL lingers longer in the blood, and the measured concentration climbs. Estrogen also influences hepatic lipase activity and the composition of HDL particles.

The Study of Women's Health Across the Nation (SWAN) is the best evidence here because it followed the same women longitudinally through the transition rather than comparing different age groups. SWAN found that total cholesterol, LDL and apolipoprotein B all rise substantially in the roughly two-year window surrounding the final menstrual period. Critically, this rise tracks with menopause stage rather than with chronological age - meaning it is the hormonal transition doing it, not simply getting older.

SWAN also documented that waist circumference increases by about 1% per year through midlife, and that visceral fat accumulation accelerates across the transition. Visceral fat is metabolically active tissue that drives triglyceride production and lowers HDL, so it compounds the estrogen effect.

The result is a lipid profile that shifts in several directions at once: LDL up, apoB up, triglycerides up, HDL functionally impaired even when the number looks stable. Our deeper dive on [why LDL rises after 45](/blog/menopause-and-cholesterol-why-ldl-rises-after-45) covers the full picture, including why an unchanged HDL number can be misleading.

GLP-1 and dual-agonist medications produce consistent improvements in triglycerides and HDL, with much smaller and less reliable effects on LDL.

In SURMOUNT-1 (NEJM 2022), serum triglycerides dropped significantly from baseline starting at week 12 and stayed down through week 72 across all tirzepatide dose groups. Post-hoc analysis by Hankosky and colleagues (2024) found broad improvements in cardiometabolic risk factors, including reductions in non-HDL cholesterol, alongside a reduced predicted 10-year atherosclerotic cardiovascular disease risk.

The head-to-head SURMOUNT-5 trial is the most informative comparison. Over 72 weeks, tirzepatide produced significantly greater improvements than semaglutide in triglycerides and HDL cholesterol. But here is the finding people tend to skip: neither drug produced a significant change in LDL or non-HDL cholesterol in that comparison.

The reason is mechanistic. Most of the lipid benefit from a GLP-1 comes indirectly, through weight loss and specifically through visceral fat reduction. Visceral fat drives triglyceride overproduction, so removing it lowers triglycerides sharply. LDL, by contrast, is governed largely by hepatic receptor activity and genetics - the things weight loss influences least.

There is a broader cardiovascular story that goes beyond lipids. The SELECT trial found semaglutide reduced major adverse cardiovascular events by 20% in people with overweight or obesity and established cardiovascular disease, without diabetes - a benefit larger than the lipid changes alone would predict. Our summary of [what SELECT found](/blog/glp1-heart-health-what-the-select-trial-found) covers the mechanisms proposed for that gap.

You get a partial match: the GLP-1 addresses the triglyceride and visceral fat side of the menopause lipid shift well, and leaves the LDL side largely untouched.

Think of the menopause lipid change as having two engines. Engine one is body composition - visceral fat accumulating around the organs, driving up triglycerides and pushing down functional HDL. A GLP-1 targets this engine directly and effectively. The visceral fat reductions seen in SURMOUNT-1 are substantial, and our article on [GLP-1s and visceral fat in menopause](/blog/glp1-menopause-visceral-fat-why-belly-fat-shifts) covers why this compartment responds particularly well.

Engine two is hepatic LDL clearance falling as estrogen declines. A GLP-1 barely touches this. If your LDL climbed from 110 to 145 across your transition, a GLP-1 is unlikely to bring it back to 110 on its own.

What this means practically is that a good outcome on a GLP-1 during menopause often looks like: triglycerides down 25-35%, HDL up modestly, waist down several inches, and LDL roughly unchanged. That can be confusing if you were expecting every number to improve, and some women read the flat LDL as the medication not working. It is working - just not on that particular pathway.

The practical implication is that LDL needs its own plan: soluble fiber, plant sterols, reduced saturated fat, and for many women a conversation about whether a statin is appropriate given their overall risk profile. Menopause is a well-recognized inflection point for cardiovascular risk assessment, as covered in our piece on [what SWAN found about heart disease risk](/blog/menopause-heart-disease-risk-what-swan-found).

Yes, and the route of administration matters more than the dose for lipid purposes.

Oral estrogen passes through the liver before entering general circulation - the first-pass effect. That hepatic exposure upregulates LDL receptors, so oral estrogen typically lowers LDL by around 10-15% and raises HDL. But the same first-pass effect increases hepatic triglyceride production, so oral estrogen raises triglycerides. In a woman who already has elevated triglycerides, that can be clinically relevant.

Transdermal estrogen - patch, gel or spray - bypasses the liver on first pass. It has a much smaller effect on LDL and is broadly neutral or mildly favorable on triglycerides. It also carries a lower venous thromboembolism risk, which is why many clinicians default to it.

So the combinations play out differently. If your main problem is high LDL and normal triglycerides, oral estrogen happens to help the number you care about. If your main problem is high triglycerides and visceral fat, transdermal estrogen plus a GLP-1 is a more coherent pairing.

The progestogen component matters too. Micronized progesterone is broadly lipid-neutral; some synthetic progestins can partially offset estrogen's HDL benefit.

One important note for anyone on both: a GLP-1 slows gastric emptying, which raises reasonable questions about oral medication absorption. The current evidence is reassuring for most oral drugs, and our article on [whether a GLP-1 changes HRT absorption](/blog/glp1-and-hrt-absorption-does-your-hormone-therapy-still-work) walks through what is known.

Ask for a full lipid panel plus apolipoprotein B, at baseline before starting a GLP-1 and again around six months.

Apolipoprotein B is the measurement worth pushing for. Each atherogenic particle carries exactly one apoB molecule, so apoB counts particles rather than measuring the cholesterol cargo inside them. This matters in menopause and in metabolic disease, where women commonly develop small dense LDL particles - more particles carrying less cholesterol each. In that pattern, a normal-looking LDL-C can badly understate actual risk. ApoB catches it.

Also worth requesting: lipoprotein(a) at least once in your life. It is largely genetically determined, does not respond meaningfully to diet, weight loss or GLP-1s, and roughly one in five people has an elevated level. It changes your risk calculation and it only needs testing once.

Timing matters for accuracy. Test at a consistent point in your dosing cycle, and note that rapid active weight loss can transiently shift lipid values. A panel drawn during a period of fast loss may not reflect your stable state - which is one argument for testing at six months rather than six weeks.

Finally, bring the full context to the appointment: your menopause stage, whether you are on HRT and by which route, your GLP-1 and dose, your family history, and blood pressure. Cardiovascular risk in midlife women is systematically underestimated, and a lipid panel read without menopause context is a lipid panel read incompletely.